Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Invested Capital (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Invested Capital for 15 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital rose 12.02% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 million, a 12.02% increase, with the full-year FY2024 number at -$64000.0, down 101.24% from a year prior.
  • Invested Capital was $1.3 million for Q3 2025 at NovaBay Pharmaceuticals, down from $4.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $17.7 million in Q1 2022 to a low of -$158.2 million in Q4 2022.
  • A 5-year average of -$1.2 million and a median of $8.3 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: plummeted 1639.04% in 2022, then skyrocketed 2904.14% in 2025.
  • NovaBay Pharmaceuticals' Invested Capital stood at $10.3 million in 2021, then tumbled by 1639.04% to -$158.2 million in 2022, then soared by 103.25% to $5.1 million in 2023, then plummeted by 101.24% to -$64000.0 in 2024, then skyrocketed by 2065.62% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Invested Capital are $1.3 million (Q3 2025), $4.4 million (Q2 2025), and $6.3 million (Q1 2025).